Prescription Digital Therapeutics
Limbix is actively researching and productizing therapies for a new therapeutic class: Prescription Digital Therapeutics. PDTs require strict compliance with FDA quality management standards and are validated through rigorous clinical trials. Limbix is developing PDTs that can be paired with existing pharmacological treatments or, in certain cases, may be indicated as standalone treatments. Upon FDA clearance, PDTs support claims and can be prescribed by a provider similarly to prescription medications.